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Self-assembled rosette nanotubes  
for incorporating hydrophobic drugs  
in physiological environments
Abstract: Rosette nanotubes (RNTs) are novel, biomimetic, injectable, self-assembled 
nanomaterials. In previous studies, materials coated with RNTs have significantly increased 
cell growth (eg, osteoblasts, chondrocytes, and endothelial cells) due to the favorable cellular 
environment created by RNTs. It has also been suggested that the tubular RNT structures formed 
by base stacking and hydrophobic interactions can be used for drug delivery, and this possibil-
ity has not been studied to date. Here we investigated methods to load and deliver tamoxifen 
(TAM, a hydrophobic anticancer drug) using two different types of RNTs:   single-base RNTs 
and twin-base RNTs. Drug-loaded RNTs were characterized by nuclear magnetic resonance 
spectroscopy, diffusion-ordered nuclear magnetic resonance spectroscopy (DOSY NMR), and 
ultraviolet-visible (UV-Vis) spectroscopy at different ratios of twin-base RNTs to TAM. The 
results demonstrated successful incorporation of hydrophobic TAM into RNTs. Importantly, 
because of the hydrophilicity of the outer surface of the RNTs, TAM-loaded RNTs were   dissolved 
in water, and thus have great potential to deliver hydrophobic drugs in various   physiological 
environments. The results also showed that twin-base RNTs further improved TAM loading. 
Therefore, this study demonstrated that hydrophobic pharmaceutical agents (such as TAM), 
once considered hard to deliver, can be easily incorporated into RNTs for anticancer treatment 
purposes.
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Introduction
There has been increasing interest in the use of injectable, biocompatible, biodegrad-
able polymers1–5 and nanoparticles6 for anticancer drug delivery applications. Methods 
based on external stimuli (ie, ultraviolet light for crosslinking) to create amphiphilic 
polymers7 or lipid drug mixtures6 to deliver water-insoluble anticancer drugs seek 
to improve drug solubility in water, increase drug bioavailability, and decrease drug 
toxicity.8 In addition, molecules with self-assembly properties have been studied for 
such applications.9–11 However, complex, chemical treatments used to create some of 
these drug carriers can result in a reduction of drug efficacy.12,13 Also, many simpler 
mixtures provide a fast, uneven release of hydrophobic drugs under physiological 
conditions, thus limiting prolonged cell–drug interactions.14,15
In order to avoid such ineffective, complex drug carrier designs, and ensure solu-
bility of water-insoluble drugs, rosette nanotubes (RNTs) have been developed and 
have shown to be advantageous in regenerative medicine due to their biologically-
derived structure and chemical properties. RNTs are novel, biomimetic, synthetic, 
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self-assembled nanomaterials. Structurally, RNTs have 
hollow channels that can be used for drug encapsulation. 
To date, there have been two types of RNTs, ie, single-base 
RNTs such as K1 (K=lysine; Figure 1) and twin-base RNTs 
such as twin-base linker molecules (TBLs) (Figure 2). Both 
types of RNTs are composed of self-assembled supramo-
lecular structures, the basic building blocks of which are 
guanine (G) and cytosine (C) DNA base pairs.16–19 The G∧C 
heteroaromatic bicyclic base of RNTs possess the Watson–
Crick donor–donor–acceptor of guanine and the acceptor–
acceptor–donor of cytosine. For K1, G∧C undergoes a 
hierarchical self-assembly process under physiological con-
ditions to form a six-member rosette (ie, supermacrocycle) 
by the formation of 18 hydrogen bonds. A lysine side chain 
is used for solubility, biocompatibility, and for imposing 
supramolecular chirality. In the case of TBL, two covalently 
connected G∧C bases self-assemble into a 6-member twin 
rosette maintained by 36 hydrogen bonds. For both types of 
RNTs, the rosettes form a stable stack with an inner diameter 
of 11 Å due to dispersion forces, base stacking interactions, 
and hydrophobic effects. The outer diameters for K1 and 
TBL are 3.5 nm and 3.8 nm, respectively (Figures 1 and 2, 
respectively).
RNTs may be able to deliver hydrophobic drugs for 
a number of reasons. The self-assembly of RNTs creates 
a hydrophobic core and hydrophilic outer surface. Thus, 
RNTs are able to incorporate water-insoluble drugs into 
their tubular structures by hydrophobic interactions with 
the core whereas their hydrophilic outer surface can shield 
such hydrophobic drugs in a physiological environment for 
subsequent prolonged release (even into the cell). RNTs 
could also be chemically functionalized with peptides to 
deliver growth factors for healthy tissue regeneration after 
the delivery of drugs to kill cancer cells. For example, 
previous studies have shown that hydrogels coated with 
Arg–Gly–Asp–Ser–Lys modified RNTs improved osteoblast 
growth compared with   unmodified hydrogels, thus making 
them attractive to potentially regenerate healthy bone in 
osteosarcoma patients.20 It has also been shown that RNTs 
are biocompatible and are able to enhance protein adsorption, 
cell adhesion, and subsequent cell functions.16,20,21 Thus, it is 
conceivable that the RNTs could not only improve healthy 
cell and tissue growth, but may also deliver hydrophobic 
drugs to target areas.
Due to its hydrophobic properties and delivery problems, 
the drug selected for this study was tamoxifen (TAM), a water-
insoluble anticancer drug used in the treatment of patients with 
estrogen receptor-positive breast cancer.22 In this study, TAM 
was incorporated into two types of RNTs, ie, K1 and TBL. 
Successful incorporation was verified using diffusion-ordered 
nuclear magnetic resonance spectroscopy (DOSY NMR) 
and ultraviolet-visible (UV-Vis) spectroscopy. Subsequent 
comparison between the two types of RNTs showed that the 
more stable TBL enabled more TAM loading. Therefore, this 
study demonstrated that RNTs are potential drug delivery 
devices for water-insoluble drugs, such as TAM, and should 
be further studied as anticancer coatings on medical devices 
or as stand-alone injectable anticancer drugs.
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Figure 1 Schematic illustration of the hierarchical assembly of K1 with a lysine side 
chain. A) The g∧C motif functionalized with a lysine side chain. B) Six g∧C motifs 
self-assemble  into  a  rosette  supermacrocycle  by  the  formation  of  18  hydrogen 
bonds, and C) The rosettes stack up to form a stable 3.5 nm diameter RNT with 
an 11 Å inner channel.
Abbreviations: C, cytosine; g, guanine; K, lysene; RNT, rosette nanotubes.
O
OO
O
HN
HN
NH
NH N N
N
N
N
N
N
NH2 NH2
H3N X
+ −
A
B
C
Figure 2 Schematic illustration of the hierarchical assembly of TBLs. A) The twin 
g∧C motif functionalized with an aminobutyl group. B) Six twin g∧C motifs self-
assemble into a twin rosette supermacrocycle held by the formation of 36 hydrogen 
bonds. C) The rosettes stack up to form a stable 3.8 nm diameter TBL with an 
11 Å inner channel. 
Abbreviations:  TAM-Kl,  tamoxifen  encapsulated  in  K1;  TAM-TBL,  tamoxifen 
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Materials and methods
Preparation of K1 and TBL
K118 (RNT with a lysine side chain) and TBL19 were synthe-
sized according to previously reported procedures.
Characterization of TAM-loaded  
K1 and TBL
K1 building block (4.30 mg) was first dissolved in deuterated 
methanol (CD3OD, 1 mL) and aged for 1 day. t-BuOH (3 µL) 
($99.5%, anhydrous; Sigma-Aldrich, St Louis, MO) was 
added as an internal standard to quantify, by 1H-NMR, the 
extent of TAM (T5648; Sigma) association with the RNTs. 
TAM (5 mg) was then added, thus resulting in a solution 
with a 5:3 TAM:K1 molar ratio. The solution was aged 
for two days to allow for the drug-loading process, and the 
supernatant was isolated for subsequent 1H-NMR studies. 
Other solutions with 5:1 and 5:5 TAM:K1 molar ratios were 
also prepared. The TBL building block (3 mg) was dissolved 
in CD3OD (1 mL) and the same procedure was followed to 
prepare mixtures with TAM (1.53 mg) resulting in a solution 
with a 5:5 molar ratio of TAM:TBL.
The supernatants were characterized by DOSY NMR 
and UV-Vis. 1H-NMR was used to observe the amount of 
drug loaded into the RNTs at various time points. All the 
NMR experiments were conducted on a Varian Direct Drive 
600 MHz spectrometer with a dual broadband probe. UV-vis 
spectra were recorded on an Agilent 8453. After this series 
of spectral analyses was completed, CD3OD was evaporated 
using a stream of nitrogen and replaced with the same volume 
of deuterated water (D2O). Any hydrophobic TAM that was 
not incorporated into the nanotubes precipitated in D2O and 
was filtered out prior to NMR studies.
The NMR peaks corresponding to the drug were moni-
tored and their integration was compared to the internal 
  standard to determine the amount of encapsulated versus free 
drug in CD3OD. Under the same experimental   conditions, 
DOSY NMR was performed to detect subtle changes 
in the diffusion coefficients of TAM in the presence of 
K1 and TBL.
For UV-Vis experiments, the supernatants of the drug-
loaded K1 and TBL were diluted with methanol to a final 
concentration of 25 µg/mL of TAM. In addition, three other 
solutions were prepared, ie, 5 µg/mL TAM, 25 µg/mL K1, 
and 25 µg/mL TBL. Each solution (3 mL) was placed in a 
1 cm × 1 cm cuvette for UV-Vis experiments. In another 
series of experiments the solutions were prepared at the same 
concentration in D2O and analyzed by UV-Vis spectroscopy. 
Because TAM was insoluble in D2O, no corresponding 
peak was recorded. Peaks from TAM and TAM-K1 were 
  compared with those from TAM and TAM-TBL.
Sample preparation of TAM-loaded K1 
and TBL for atomic force microscopy
For atomic force microscopy (AFM) experiments, samples 
prepared in D2O were diluted to 25 µg/mL and imaged using 
a MultiMode Nanoscope IV AFM (Digital   Instruments/Veeco 
Instruments, New York, NY) equipped with an E scanner. 
Height profiles were measured using silicon cantilevers 
  (MikroMasch USA, Inc., Portland, OR) with low spring 
  constants of 4.5 N/m in tapping mode. To obtain a clear 
image of the surface, a low scan rate (0.5–1 Hz) and   amplitude 
  setpoints (1 V) were chosen during   measurements.19 Clean mica 
  substrates (Mica-Grade V-4 SPI, Catalog number 01918-CF 
and Lot number 1100315) were prepared and the samples 
were deposited by   spin-coating 20 µL of each   solution at 
2000 rpm for 20 seconds.
Statistical analysis
Data are expressed as standard error of the mean. Statistics 
were performed using a Student’s one-tailed t-test, with 
P , 0.05 being considered statistically significant.
Results
Because of their large molecular weight and long relaxation 
time, K1 and TBL were not detected by 1H-NMR spectroscopy. 
Thus as the drug becomes encapsulated by the RNTs, its inte-
gration by 1H-NMR decreases relative to the internal standard 
(t-BuOH). At the TAM:K1 molar ratio of 5:3 (Table 1), the 
incorporation of the drug reached an average maximum of 22% 
within one day (ca. 0.254 mg of TAM per 1 mg of K1).
Table 1 1H-NMR spectroscopy of TAM-K1 mixture (5:3 molar 
ratio) at different time intervals monitored at 7.25 ppm
Time (h) 0 1 2 3 4 5 24 48
1H integration  2.20 2.18 2.09 2.07 2.02 2.0 1.69 1.68
Abbreviation: TAM-K1, tamoxifen encapsulated in K1.
Table 2  1H-NMR spectroscopy of TAM-K1 and TAM-TBL at 
different molar ratios monitored at 2.68–3 ppm
TAM-K1 molar ratio (5:1) (5:3) (5:5) (5:5)
1H integration of TAM 
before encapsulation
0.03 2.33 2.33 1
1H integration of TAM 
after encapsulation
0.02 1.85 1.72 0.72
Average change 2.13% 22% 26.5% 30%
Abbreviations:  TAM-K1,  tamoxifen  encapsulated  in  K1;  TAM-TBL,  tamoxifen 
encapsulated in TBL.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 3 DOSY NMR of TAM and of TAM-K1 mixture (5:5 molar ratio)
TAM peaks Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 Peak 6 Average
Chemical shift (ppm) 6.7 6.55 3.9 3.1 2.58 2.41 –
Diffusion coefficient  
(m2/s) before
7.2 7.4 7.2 7.4 7.4 7 7.27
Diffusion coefficient  
(m2/s) after
5.4 5.4 5.6 5.6 5.2 5.2 5.37
Abbreviation: TAM-K1, tamoxifen encapsulated in K1.
Results also showed that more TAM was incorporated as 
additional K1 was added (Table 2). Interestingly, the more 
stable and more hydrophobic TBL incorporated a slightly 
larger amount of TAM relative to K1 (11.3% ± 2.1% greater 
loading), as shown in Table 2. To provide further evidence 
for the incorporation of TAM into K1 and TBL, changes in 
the diffusion coefficient of TAM obtained from the DOSY 
NMR experiments (Tables 3 and 4) were measured and 
were found to vary from 7.27 to 5.37 for K1, and from 7.27 
to 5.48 for TBL. This reduction in diffusion coefficient is 
indicative of an interaction between the drug and the larger 
RNT assemblies.
Incorporation of  TAM in K1 and TBL was also inves-
tigated by UV-Vis experiments (Figure 3), which showed 
significantly different profiles for TAM-K1 and TAM-TBL in 
methanol. When the UV-Vis spectra were recorded in water, 
which mimics the actual physiological environment in the 
body, the UV-Vis profiles of K1 and TBL were significantly 
different from those of TAM-K1 and TAM-TBL, respectively. 
This result indicated once again that TAM does bind to the 
RNTs.
Tapping mode AFM (Figure 5) showed different heights 
for the aqueous solutions of RNTs in the presence and in the 
absence of TAM. Height measurements showed a signifi-
cantly greater value for RNT-encapsulated TAM (Figure 6). 
The average heights were 2.91 nm, 7.40 nm, 3.02 nm, 
and 6.22 nm for K1, TAM-K1, TBL, and   TAM-TBL, 
  respectively. While the values for the complexes are dramati-
cally high relative to the uncomplexed RNTs, they do sup-
port the existence of an interaction between drug and RNTs 
(whose exact nature is still unknown at this stage).
Discussion
The drug-loading capacity of K1 and TBL was inves-
tigated here for the first time under various conditions 
using 1H-NMR. For equivalent concentrations of TAM and 
RNTs, ca. 30% of the hydrophobic anticancer drug was 
incorporated. The amount of RNTs present was crucial to 
how much TAM could be loaded. Successful TAM loading 
was further   confirmed by DOSY NMR experiments where 
diffusion coefficients of TAM diminished significantly after 
interacting with the RNTs. UV-Vis experiments supported 
the presence of an interaction between TAM and RNTs. 
Although our experiments did not establish how TAM mol-
ecules may be incorporated into the RNTs, the hypochromic 
effect observed in the UV-Vis spectra of TAM-TBL suggests 
that TAM molecules may be intercalating between the G∧C 
bases.   Furthermore, AFM height profiles showed a dramatic 
increase in RNT cross-section as a result of interaction with 
TAM. It should also be noted the RNTs maintained their 
structural integrity after TAM loading, which has been 
shown to be essential for their biological activity.20
TAM is widely used as an anticancer drug, but its 
water insolubility has limited its delivery and release in 
physiological environments. Previous studies have inves-
tigated drug delivery systems for hydrophobic drugs.23,24 
A variety of water-insoluble drugs have been incorporated 
in biodegradable polymers, eg, poly(lactic-co-glycolic 
acid [PLGA]) and nonbiodegradable polymers, eg, 
poly(ethylene-co-vinyl acetate, EVAc).25,26 However, sev-
eral issues associated with these polymers have been raised 
such as the presence of residual organic solvents, toxicity 
of photoinitiators, and complex material preparation.25,27 
Table 4 DOSY NMR of TAM and of TAM-TBL mixture (5:5 molar ratio) 
TAM peaks Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 Peak 6 Average
Chemical shift (ppm) 6.7 6.55 3.9 3.1 2.58 2.41 –
Diffusion coefficient  
(m2/s) before
7.2 7.4 7.2 7.4 7.4 7 7.27
Diffusion coefficient  
(m2/s) after
5.3 5.4 5.6 5.6 5.6 5.4 5.48
Abbreviations: TAM, tamoxifen; TAM-TBL, tamoxifen encapsulated in TBL.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 UV-Vis spectra recorded in methanol of A) TAM (5 µg/mL), B) K1 (left) and TBL (right) (25 µg/mL), C) TAM-K1 (left) and TAM-TBL (right) (25 µg/mL).
Abbreviations: K1, rosette nanotubes with lysine; TAM, tamoxifen; TAM-K1, tamoxifen encapsulated in K1; TAM-TBL, tamoxifen encapsulated in TBL.
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Figure 4 UV-Vis spectra recorded in water of A) TAM-K1 (left) and TAM-TBL (right), and B) K1 (left) and TBL (right). All samples were at a concentration of 25 µg/mL.
Abbreviations: K1, rosette nanotubes with lysine; TAM, tamoxifen; TAM-K1, tamoxifen encapsulated in K1; TAM-TBL, tamoxifen encapsulated in TBL.
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Figure 5 Tapping mode AFM height images of A) K1, B) TAM-K1, C) TBL, and D) TAM-TBL.
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For example, PLGA is one of the most widely used drug 
delivery agents, but its acidic degradation byproducts (lactic 
acid and glycolic acid) possess some degree of cytotoxici-
ty.28 In addition, some studies have found that the organic 
solvents used in the formulation of PLGA (eg, CH2Cl2), 
still present in trace amounts, could negatively influence 
surrounding cells and tissues.25
In situ injectable drug delivery systems have also received 
much attention. Firstly, such methods are less invasive and 
less painful compared with implant insertion, which requires 
local anesthesia and surgery. Secondly, localized or systemic 
drug delivery can be achieved for prolonged periods of time, 
typically ranging from one to several months.27 For instance, 
polyethylene glycol-oligo-glycolyl-acrylate can be cross-
linked to encapsulate drugs using a photoinitiator such as 
eosin. However, such methods are restricted to the   correct 
wavelength and the accessibility to a light source. More 
importantly, the potential toxicity of the photo crosslinker 
is another source of concern.
Therefore, compared with conventional drug delivery 
systems, RNTs as described here can self-assemble in situ 
and are water soluble, biocompatible nanomaterials, suitable 
for hydrophobic drug incorporation. Moreover, in the present 
study, TBL were introduced as a new generation of self-
assembled RNTs because they have six twin G∧C base units, 
which leads to stronger hydrogen bond networks, stronger 
π-stacking interactions, and as a result a more stable RNT. 
Although this study demonstrated the ability of RNTs to load 
TAM in water, we envision that several other hydrophobic 
drugs could be excellent candidates for encapsulation and 
delivery by the RNTs.
Conclusions
In summary, the relatively simple procedure described in 
this study to load TAM into RNTs could offer an ideal drug 
delivery system for hydrophobic drugs. The biocompatibility, 
amphiphilic nature of the RNTs solve a number of drug deliv-
ery problems, including limited water solubility and bioavail-
ability in physiological environments. RNT-encapsulated 
TAM should be further studied as an anticancer coating on 
current implants or as stand-alone injectable drug delivery 
vehicle. Additional in vitro studies to study drug-release 
kinetics and the bioactivity of TAM after incorporation in 
RNTs are currently underway.
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